Alzheimer’s & Parkinson’s Disease: How Stem Cells are Making a Difference
For its annual public panel, the NYSCF Research Institute brought together leading stem cell scientists and other experts to explain how stem cell research will help find new treatments for Alzheimer’s and Parkinson’s disease. This year’s panel was moderated by Zach Hall, PhD, Board Member, The New York Stem Cell Foundation, and Former Director, National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH).
<iframe src=”//player.vimeo.com/video/86515539?title=0&byline=0&portrait=0″ width=”625″ height=”351″ frameborder=”0″ webkitallowfullscreen mozallowfullscreen allowfullscreen></iframe>
For its annual public panel, the NYSCF Research Institute brought together leading stem cell scientists and other experts to explain how stem cell research will help find new treatments for Alzheimer’s and Parkinson’s disease.
- Samuel Gandy, MD, PhD, Associate Director, Mount Sinai Alzheimer’s Disease Research Center; Chairman Emeritus of the National Medical and Scientific Advisory Council of the Alzheimer’s Association
- Scott Noggle, PhD, Director, The NYSCF Research Institute Laboratory; The NYSCF – Charles Evans Senior Research Fellow for Alzheimer’s Disease
- Melissa J. Nirenberg, PhD, Associate Professor of Neurology, NYU School of Medicine; Associate Director of Clinical Services, NYU Parkinson’s and Movement Disorders Center
- Susan L. Solomon, JD, Chief Executive Officer and Co-founder, The New York Stem Cell Foundation
In past years, NYSCF’s public outreach panels have focused on stem cell research in relation to Alzheimer’s disease, diabetes, the important role stem cell research plays in accelerating research, and the political controversy surrounding this groundbreaking science. Previous notable panel participants include: Nobel Laureate and Director of the National Cancer Institute, Dr. Harold Varmus; ten-time Olympic medalist, Gary Hall, Jr.; artist, Chuck Close; patient advocates Michael J. Fox and Alexandra Reeve; and Greg Simon, Senior Vice President of Worldwide Policy at Pfizer. The 2010 panel had our best response to date and was at capacity with over 400 attendees.